(Q38207137)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24766435%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

title

Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24766435%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24766435%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

author name string

Toby A Eyre

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24766435%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Dalia Khan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24766435%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Georgina W Hall

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24766435%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

publication date

21 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24766435%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Haematology

16 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24766435%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

volume

93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24766435%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24766435%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

page(s)

455-468

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24766435%20AND%20SRC:MED&resulttype=core&format=json

Anaplastic Large Cell Lymphoma.

16 March 2020

cites work

1 reference

Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes

21 January 2018

1 reference

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

21 January 2018

1 reference

CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35.

21 January 2018

1 reference

ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum.

21 January 2018

1 reference

Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms

21 January 2018

1 reference

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

21 January 2018

1 reference

Childhood non-Hodgkin lymphomas in the United Kingdom: findings from the UK Children's Cancer Study Group

21 January 2018

1 reference

Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter study

21 January 2018

1 reference

Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients.

21 January 2018

1 reference

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

21 January 2018

1 reference

ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

21 January 2018

1 reference

Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers.

21 January 2018

1 reference

Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion.

21 January 2018

1 reference

Characterization of the expression of the ALK receptor tyrosine kinase in mice

21 January 2018

1 reference

A ligand-inducible epidermal growth factor receptor/anaplastic lymphoma kinase chimera promotes mitogenesis and transforming properties in 3T3 cells

21 January 2018

1 reference

Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage.

21 January 2018

1 reference

The anaplastic lymphoma kinase in the pathogenesis of cancer

21 January 2018

1 reference

21 January 2018

Nucleophosmin and cancer

1 reference

Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity

21 January 2018

1 reference

Translocations involving anaplastic lymphoma kinase (ALK).

21 January 2018

1 reference

Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma.

21 January 2018

1 reference

NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.

21 January 2018

1 reference

Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target

21 January 2018

1 reference

Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death

21 January 2018

1 reference

The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner

21 January 2018

1 reference

Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies

21 January 2018

1 reference

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

21 January 2018

1 reference

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials

21 January 2018

1 reference

Dual ALK and MYC rearrangements leading to an aggressive variant of anaplastic large cell lymphoma

21 January 2018

1 reference

C-MYC rearrangement may induce an aggressive phenotype in anaplastic lymphoma kinase positive anaplastic large cell lymphoma: Identification of a novel fusion gene ALO17/C-MYC.

21 January 2018

1 reference

Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience

21 January 2018

1 reference

Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial

21 January 2018

1 reference

Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma.

21 January 2018

1 reference

Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype

21 January 2018

1 reference

Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.

21 January 2018

1 reference

Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

21 January 2018

1 reference

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

21 January 2018

1 reference

Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

21 January 2018

1 reference

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy

21 January 2018

1 reference

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

21 January 2018

1 reference

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.

21 January 2018

1 reference

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

21 January 2018

1 reference

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells

21 January 2018

1 reference

Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas

21 January 2018

1 reference

Crizotinib in anaplastic large-cell lymphoma

21 January 2018

1 reference

The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination

21 January 2018

1 reference

Hemophagocytic lymphohistiocytosis associated with a lymphohistiocytic pattern anaplastic large cell lymphoma: a case report

21 January 2018

1 reference

21 January 2018

1 reference

Clinical analysis and prognostic significance of haemophagocytic lymphohistiocytosis-associated anaplastic large cell lymphoma in children.

21 January 2018

1 reference

Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification

21 January 2018

1 reference

Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study

21 January 2018

1 reference

Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens

21 January 2018

1 reference

Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.

21 January 2018

1 reference

Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial.

21 January 2018

1 reference

Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group

21 January 2018

1 reference

Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study

21 January 2018

1 reference

Limited stage I disease is not necessarily indicative of an excellent prognosis in childhood anaplastic large cell lymphoma.

21 January 2018

1 reference

Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III tri

21 January 2018

1 reference

Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology

21 January 2018

1 reference

Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941.

21 January 2018

1 reference

Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents

21 January 2018

1 reference

Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report.

21 January 2018

1 reference

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

21 January 2018

1 reference

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference